Cell Culture and iPS Core

细胞培养和 iPS 核心

基本信息

批准号：
9762896
负责人：
EDWARD E MORRISEY
金额：
$ 14.95万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-07-01 至 2022-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9762896
关键词：
3-Dimensional Advocate Biological CRISPR/Cas technology Cell Culture Techniques Cell Line Cells Collaborations Core Facility Development Developmental Biology Digestive System Disorders Dimensions Disease Ductal Epithelial Cell Endothelial Cells Ensure Epithelial Cells Esophageal Feedback Fibroblasts Fostering Future Gene Expression Gene-Modified Grant Hepatocyte Human Human Resources Infrastructure Institutes Instruction Intestines Leadership Liver Liver diseases Maintenance Measures Mission Molecular Mus Mycoplasma Infections Names National Institute of Diabetes and Digestive and Kidney Diseases Nature Organoids Pancreas Pennsylvania Process Protocols documentation Quality Control RNA Interference Regenerative Medicine Reproducibility Research Services Standardization Structure of thyroid parafollicular cell System Techniques Technology Time Tissues Universities Viral Vector Vision bile duct cancer cell cost effective cost effectiveness embryonic stem cell established cell line experimental study in vivo induced pluripotent stem cell member programs ranpirnase repository service member stem cell technology stem-like cell three dimensional cell culture tool translational medicine

项目摘要

PROJECT SUMMARY (CELL CULTURE AND iPS CORE) The Cell Culture and iPS Core (CCiC) facility is unique on the University of Pennsylvania campus and in the region. It serves a tremendous need by Center of Molecular Studies in Digestive and Liver Diseases (abbreviated as CMSDLD, which is the NIDDK P30 Digestive Diseases Research Core Center) members for services and technologies underlying Specific Aims related to primary cells and established cell lines, 3D culture systems (organotypic culture and organoids), manipulating gene expression in cell lines through RNA interference and CRISPR/Cas9, and the application of induced pluripotent stem cells (iPS) that have been genetically reprogrammed to an embryonic stem cell-like condition and differentiating such cells to discrete lineages (GI, pancreas, liver). Furthermore, the CCiC provides a rich repository of c cell lines (2D and 3D) that are well annotated for identity, passage and free of Mycoplasma infection thereby providing quality control, rigor and reproducibility. The CCiC provides standardized protocols and regular orientation and instruction, which prove to be cost-effective measures. There are emerging projects related to the use of iPS technology to correct disease states in enteroids and hepatocytes, remarkable illustrations of translational medicine fueled by the CCiC. Through its services, technologies, quality control and time/cost-effectiveness, the CCiC advances the CMSDLD's vision and missions on behalf of members/associate members/personnel.

项目摘要（细胞培养和IPS核心）细胞培养和IPS核心（CCIC）设施在宾夕法尼亚大学校园和地区。它在消化和肝病中的分子研究中心满足了极大的需求（缩写为CMSDLD，即NIDDK P30消化疾病研究核心中心）成员服务和技术与原代细胞和已建立的细胞系相关的特定目的，3D 培养系统（器官培养和器官），通过RNA操纵基因表达干扰和CRISPR/CAS9，以及已诱导的多能干细胞（IP）的应用从基因重编程为胚胎干细胞状的条件，并将此类细胞区分开为离散谱系（GI，胰腺，肝脏）。此外，CCIC提供了C细胞系（2D和3D）的丰富存储库可以很好地注释身份，通过并没有支原体感染，从而提供质量控制，严格和可重复性。 CCIC提供标准化的协议以及定期方向和指令，这被证明是具有成本效益的措施。有与使用IPS技术有关的新兴项目正确疾病状态在肠动细胞和肝细胞中 CCIC。通过其服务，技术，质量控制和时间/成本效益，CCIC的进步 CMSDLD代表成员/同学成员/人员的愿景和任务。